Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase

Oncotarget

Volumn 6, Issue 30, 2015, Pages 30317-30326

  Wang, Liang ^a   Wang, Hua ^a   Wang, Jing Hua ^a   Xia, Zhong Jun ^a   Lu, Yue ^a   Huang, Hui Qiang ^a   Jiang, Wen Qi ^a   Zhang, Yu Jing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Asparaginase; Epstein Barr virus; Extranodal NK T cell lymphoma; Minimal residual disease; Prognosis

Indexed keywords

ASPARAGINASE; LACTATE DEHYDROGENASE; VIRUS DNA; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; B SYMPTOM; BLOOD LEVEL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATIONAL STUDY; DISEASE ASSESSMENT; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS SCORE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; ADVERSE EFFECTS; CHEMORADIOTHERAPY; COMPLICATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; KAPLAN MEIER METHOD; LYMPHOMA, EXTRANODAL NK-T-CELL; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY DOSAGE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84945143817     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4505     Document Type: Article

References (31)

1. Yoon TY, Lee HT, Chang SH. Nasal-type T/natural killer cell angiocentric lymphoma, Epstein-Barr virus-associated, and showing clonal T-cell receptor gamma gene rearrangement. The British journal of dermatology. 1999; 140:505-508.
2. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R and International Peripheral TCLP. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009; 113:3931-3937.
3. Jiang L, Li SJ, Jiang YM, Long JX, Wang RS, Su J, Zhang Y. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis. Leukemia & lymphoma. 2014; 55:1038-1048.
4. Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, Ping L, Ying Z, Zhang C, Deng L, Liu W, Zhu J. A prospective phase II study of L-asparaginase-CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. Journal of hematology & oncology. 2013; 6:44.
5. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013; 119:348-355.
6. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. American journal of hematology. 2008; 83:795-799.
7. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Medical oncology. 2014; 31:860.
8. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:4410-4416.
9. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011; 117:1834-1839.
10. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. British journal of haematology. 2000; 111:239-246.
11. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Reviews in medical virology. 2008; 18:305-319.
12. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer research. 2003; 63:2028-2032.
13. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8:29-34.
14. Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, Song YW, Liu YP, Fang H, Ren H, Wu RY, Chen B, Zhang XM, Lu NN, Zhou LQ, Li YX. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012; 120:2003-2010.
15. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. International journal of hematology. 2012; 96:617-623.
16. Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014; 28:865-870.
17. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24:612-618.
18. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, Hyo R, Suzumiya J, Nakamura S, Kawa K, Oshimi K, Group NK-cTS. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011; 118:6018-6022.
19. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:2141-2149.
20. Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y. Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Medical oncology. 2013; 30:723.
21. Wang L, Wang H, Li PF, Lu Y, Xia ZJ, Huang HQ, Zhang YJ. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Annals of hematology. 2015; 94:1381-8.
22. Wang L, Wu-Xiao ZJ, Chen XQ, Zhang YJ, Lu Y, Xia ZJ. Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma. Leukemia & lymphoma. 2014:1-6.
23. Wang L, Xia ZJ, Lu Y, Wang QX, Niu SQ, Huang HQ, Zhang YJ. A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma. Leukemia & lymphoma. 2015:1-7.
24. Zhang J, Wang WD, Geng QR, Wang L, Chen XQ, Liu CC, Lv Y. Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma. PloS one. 2014; 9:e94637.
25. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005; 106:3785-3790.
26. Lin ZX, Bai B, Cai QC, Cai QQ, Wang XX, Wu XY, Huang HQ. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T-and natural killer cell lymphomas. Medical oncology. 2012; 29:3522-3528.
27. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO. 2011; 22:1859-1864.
28. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:285-288.
29. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17:1244.
30. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004; 100:1162-1170.
31. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011; 117:3750-3757.